Wedbush Issues Positive Forecast for Dianthus Therapeutics (NASDAQ:DNTH) Stock Price

Dianthus Therapeutics (NASDAQ:DNTH) had its price target upped by Wedbush from $55.00 to $80.00 in a report published on Tuesday,Benzinga reports. The firm currently has an outperform rating on the stock.

Several other equities analysts also recently weighed in on DNTH. Jefferies Financial Group set a $98.00 price target on Dianthus Therapeutics and gave the company a “buy” rating in a report on Monday. Truist Financial increased their price objective on shares of Dianthus Therapeutics from $63.00 to $110.00 and gave the company a “buy” rating in a research report on Monday. HC Wainwright lifted their target price on shares of Dianthus Therapeutics from $47.00 to $130.00 and gave the stock a “buy” rating in a report on Monday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Dianthus Therapeutics in a research note on Wednesday, January 21st. Finally, Oppenheimer increased their price target on shares of Dianthus Therapeutics to $145.00 and gave the company an “outperform” rating in a report on Monday. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $115.33.

Dianthus Therapeutics Stock Up 9.7%

DNTH stock opened at $86.92 on Tuesday. The business has a 50 day moving average of $50.09 and a 200 day moving average of $41.61. The firm has a market cap of $3.76 billion, a PE ratio of -21.20 and a beta of 1.56. Dianthus Therapeutics has a twelve month low of $13.36 and a twelve month high of $86.97.

Dianthus Therapeutics (NASDAQ:DNTH) last released its earnings results on Monday, March 9th. The company reported ($1.43) EPS for the quarter, missing the consensus estimate of ($0.97) by ($0.46). Dianthus Therapeutics had a negative return on equity of 41.34% and a negative net margin of 7,973.33%.The company had revenue of $0.57 million during the quarter, compared to the consensus estimate of $0.40 million. On average, research analysts expect that Dianthus Therapeutics will post -2.61 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Dianthus Therapeutics

Large investors have recently bought and sold shares of the business. Patient Square Capital LP bought a new stake in shares of Dianthus Therapeutics in the third quarter worth approximately $4,919,000. XTX Topco Ltd bought a new position in Dianthus Therapeutics during the second quarter valued at approximately $503,000. Sio Capital Management LLC lifted its position in Dianthus Therapeutics by 101.8% during the second quarter. Sio Capital Management LLC now owns 236,070 shares of the company’s stock valued at $4,398,000 after purchasing an additional 119,073 shares during the period. Vanguard Group Inc. boosted its holdings in Dianthus Therapeutics by 13.6% in the third quarter. Vanguard Group Inc. now owns 1,642,198 shares of the company’s stock worth $64,620,000 after purchasing an additional 196,117 shares during the last quarter. Finally, Ensign Peak Advisors Inc purchased a new stake in Dianthus Therapeutics in the second quarter worth approximately $2,504,000. 47.53% of the stock is currently owned by institutional investors.

Dianthus Therapeutics News Roundup

Here are the key news stories impacting Dianthus Therapeutics this week:

• Positive Sentiment: Early “GO” decision in the phase 3 CAPTIVATE CIDP trial after an interim responder analysis — company met GO criteria with 20 confirmed responders and will keep the Part A dose, accelerating development and creating a near‑term catalyst (top‑line CIDP data expected year‑end 2026). Globe Newswire — Early GO Decision
• Positive Sentiment: Encouraging clinical update drove sharp intraday gains — multiple outlets report shares jumped after the interim data and management commentary indicating the program is advancing (investor enthusiasm for a late‑stage autoimmune asset). Investing.com — Stock Surges on CIDP Trial Success
• Positive Sentiment: Multiple analyst upgrades and big price‑target increases (Raymond James to strong‑buy/$123, Robert W. Baird to $132, HC Wainwright to $130, Truist to $110, Guggenheim reiteration) are reinforcing bullish sentiment and providing supporting coverage. Yahoo Finance — Guggenheim Reiterates Buy
• Neutral Sentiment: Analyses and writeups are re‑examining DNTH valuation after large share gains (12–13x over two years); these pieces help frame risk/reward but don’t change near‑term fundamentals. Investors.com — What’s Going On?
• Neutral Sentiment: Company disclosed an AI integration-related cyber/privacy/reputational risk in filings — worth monitoring operationally but not an immediate stock driver versus clinical and financing news. TipRanks — AI Integration Risk
• Negative Sentiment: Announced proposed $400M underwritten public offering (plus 30‑day option for up to $60M) — dilutive capital raise that triggered a stock pullback as investors weigh share issuance against cash runway and program funding. Globe Newswire — $400M Offering
• Negative Sentiment: Q4 earnings missed consensus (loss of $1.43 vs. est. ~$0.97), highlighting ongoing operating losses and the company’s need for external funding — a reminder that clinical progress, not current revenue, is the primary value driver. Zacks — Q4 Loss, Miss

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.